|
US2957906A
(en)
|
1955-10-25 |
1960-10-25 |
Monsanto Chemicals |
Ketones
|
|
US3227473A
(en)
|
1963-12-12 |
1966-01-04 |
Julian S Halbern |
Check identification
|
|
JPS5752354B2
(enExample)
|
1973-10-22 |
1982-11-06 |
|
|
|
JPS5069091U
(enExample)
|
1973-10-25 |
1975-06-19 |
|
|
|
US3980674A
(en)
|
1974-01-28 |
1976-09-14 |
Delmar Chemicals Limited |
2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene
|
|
JPS5132733A
(en)
|
1974-09-10 |
1976-03-19 |
Kyowa Hakko Kogyo Kk |
Josozai |
|
US3954913A
(en)
|
1975-01-06 |
1976-05-04 |
The Standard Oil Company |
Stabilized nitrile polymers
|
|
JPS5188631U
(enExample)
|
1975-01-10 |
1976-07-15 |
|
|
|
JPS5188631A
(en)
|
1975-01-31 |
1976-08-03 |
|
Hiiryoyosatsukinzai oyobi sonoseizoho
|
|
US4143054A
(en)
|
1977-11-04 |
1979-03-06 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane- and 7-oxabicycloheptene compounds
|
|
US4218478A
(en)
|
1979-01-05 |
1980-08-19 |
Ruiko Oiwa |
Trichostatin as an antiprotozoal agent
|
|
US4760067A
(en)
|
1979-08-15 |
1988-07-26 |
Merck & Co., Inc. |
Allylsulfoxide enzyme inhibitors
|
|
US4298752A
(en)
|
1980-09-19 |
1981-11-03 |
Regents Of The University Of California |
Cycloadduct precursors of cantharidin and method
|
|
US4614825A
(en)
|
1982-05-17 |
1986-09-30 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane and 7-oxabicycloheptene compounds
|
|
US4463015A
(en)
|
1982-08-18 |
1984-07-31 |
E. R. Squibb & Sons, Inc. |
Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
|
|
US4518696A
(en)
|
1983-01-11 |
1985-05-21 |
Chr. Hansen's Laboratory, Inc. |
Stabilized liquid bacterial suspension for oral administration to animals
|
|
US4524151A
(en)
|
1983-11-14 |
1985-06-18 |
E. R. Squibb & Sons, Inc. |
7-Oxabicycloheptane thio ethers useful as cardiovascular agents
|
|
JPS61176523A
(ja)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
制癌剤
|
|
US4654355A
(en)
|
1985-08-01 |
1987-03-31 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs
|
|
US4816579A
(en)
|
1986-06-04 |
1989-03-28 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
|
|
US4851553A
(en)
|
1986-06-04 |
1989-07-25 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane amido-carboxylic acids
|
|
US4851423A
(en)
|
1986-12-10 |
1989-07-25 |
Schering Corporation |
Pharmaceutically active compounds
|
|
SU1553533A1
(ru)
|
1988-01-28 |
1990-03-30 |
Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко |
Способ получени 1,4-бисполифторалкил-7-оксбицикло [2.2.1]гептанов
|
|
JP2789365B2
(ja)
|
1988-12-14 |
1998-08-20 |
塩野義製薬株式会社 |
ジカルボン酸モノエステルおよびその製造法
|
|
RU2015980C1
(ru)
|
1990-02-06 |
1994-07-15 |
Е.Р.Сквибб энд Санз, Инк. |
7-оксабициклогептилзамещенные гетероциклические амиды или их стереоизомеры в качестве антагонистов рецепторов тромбоксана
|
|
US5763647A
(en)
|
1990-03-30 |
1998-06-09 |
Shionogi & Co., Ltd. |
Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
|
|
WO1991018891A1
(en)
|
1990-06-04 |
1991-12-12 |
Pfizer Inc. |
Aromatic pyrrolidine and thiazolidine amides
|
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
US5266710A
(en)
|
1990-12-18 |
1993-11-30 |
Patel Ramesh N |
(Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
|
|
US5206386A
(en)
|
1991-03-20 |
1993-04-27 |
Isp Investments Inc. |
Controlled release N-substituted pyrrolidone esters and process for the use thereof
|
|
US5580858A
(en)
|
1991-06-10 |
1996-12-03 |
Alberta Research Council |
Immunosuppressive and tolerogenic modified Lewisx compounds
|
|
JP3134233B2
(ja)
|
1991-07-26 |
2001-02-13 |
株式会社林原生物化学研究所 |
α−グリコシル ケルセチンとその製造方法並びに用途
|
|
US5326898A
(en)
|
1992-02-11 |
1994-07-05 |
Allergan, Inc. |
Substituted phenylethenyl compounds having retinoid-like biological activity
|
|
US6602713B1
(en)
|
2001-02-09 |
2003-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
|
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
|
US5518993A
(en)
|
1994-08-12 |
1996-05-21 |
Buckman Laboratories International, Inc. |
Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endothal and salts thereof
|
|
US5770382A
(en)
|
1994-12-30 |
1998-06-23 |
Ligand Pharmaceuticals, Inc. |
Tricyclic retinoids, methods for their production and use
|
|
US6222055B1
(en)
|
1995-07-06 |
2001-04-24 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. |
Hydrolyzable and polymerizable and/or polyadditive silanes
|
|
DE19600707B4
(de)
|
1996-01-11 |
2004-02-19 |
Glüsenkamp, Karl-Heinz, Dr. |
Biyclische Anhydrid-Wirkstoff-Verbindungen, Verfahren zur Herstellung und Verwendung derselben
|
|
US5968965A
(en)
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
|
US5925651A
(en)
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6387673B1
(en)
|
1997-05-01 |
2002-05-14 |
The Salk Institute For Biological Studies |
Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
|
|
CN1282218A
(zh)
|
1997-10-15 |
2001-01-31 |
波拉克斯生物药品 |
使用砷化合物治疗原发性及转移性肿瘤疾病的组合物及方法
|
|
US6632823B1
(en)
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
|
US6262116B1
(en)
|
1998-01-23 |
2001-07-17 |
Sloan-Kettering Institute For Cancer Research |
Transcription therapy for cancers
|
|
CA2334222C
(en)
|
1998-06-05 |
2010-02-09 |
Technion Research And Development Foundation Ltd. |
Insulin supplemented infant formula
|
|
AUPP466598A0
(en)
|
1998-07-14 |
1998-08-06 |
University Of Newcastle Research Associates Limited, The |
Product and process
|
|
US20040110822A1
(en)
|
1998-07-14 |
2004-06-10 |
The University Of Newcastle Research Associates |
Anhydride modified cantharidin analogues useful in the treatment of cancer
|
|
ATE279407T1
(de)
|
1998-08-07 |
2004-10-15 |
Applied Research Systems |
Fsh mimetika zur behandlung von infertilität
|
|
US20020151515A1
(en)
|
1999-06-18 |
2002-10-17 |
Roberts Bruce L. |
Preparation and use of superior vaccines
|
|
US6949624B1
(en)
|
1999-08-03 |
2005-09-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloning of the human nuclear receptor co-repressor gene
|
|
MXPA02002505A
(es)
|
1999-09-08 |
2004-09-10 |
Sloan Kettering Inst Cancer |
Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
|
|
US7605185B2
(en)
|
1999-11-23 |
2009-10-20 |
Gerhart Graupner |
Treatment of arrhythmia by retinoids affecting signal transduction
|
|
WO2001062242A1
(en)
|
2000-02-24 |
2001-08-30 |
Biocryst Pharmaceuticals, Inc. |
Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
|
|
JP4518627B2
(ja)
|
2000-03-14 |
2010-08-04 |
旭化成イーマテリアルズ株式会社 |
ヒドロキシポリアミド
|
|
AU2001248701A1
(en)
|
2000-03-24 |
2001-10-03 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
DE10038043B4
(de)
|
2000-08-02 |
2006-09-07 |
Walter, Michael, Dr. |
Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
WO2002024680A1
(en)
|
2000-09-21 |
2002-03-28 |
Smithkline Beecham P.L.C. |
Imidazole derivatives as raf kinase inhibitors
|
|
AU2001296558A1
(en)
|
2000-10-03 |
2002-04-15 |
Oncopharmaceutical, Inc. |
Inhibitors of angiogenesis and tumor growth for local and systemic administration
|
|
WO2002029018A2
(en)
|
2000-10-06 |
2002-04-11 |
Michigan State University |
Divinyl ether synthase gene and protein, and uses thereof
|
|
CN1213050C
(zh)
|
2000-11-23 |
2005-08-03 |
拜尔公司 |
氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
|
|
US20020177692A1
(en)
|
2001-04-16 |
2002-11-28 |
Myriad Genetics, Incorporated |
BCL-XL-interacting protein and use thereof
|
|
AU2002242175A1
(en)
|
2001-02-16 |
2002-09-04 |
Brigham And Women's Hospital |
Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
|
|
AUPR392301A0
(en)
|
2001-03-23 |
2001-04-26 |
University Of Newcastle Research Associates Limited, The |
Protein phosphatase inhibitors
|
|
US20040253637A1
(en)
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
DE10122898A1
(de)
|
2001-05-11 |
2002-11-14 |
Haarmann & Reimer Gmbh |
Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks
|
|
US20070015144A9
(en)
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
|
WO2003014062A1
(en)
|
2001-08-03 |
2003-02-20 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services |
Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents
|
|
US20040010045A1
(en)
|
2001-09-07 |
2004-01-15 |
Taolin Yi |
Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
|
|
US7179450B2
(en)
|
2001-09-20 |
2007-02-20 |
Medi-Physics, Inc. |
Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
|
|
WO2003032921A2
(en)
|
2001-10-16 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
|
NZ544689A
(en)
|
2001-11-06 |
2007-08-31 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
|
AU2002353845A1
(en)
|
2001-11-23 |
2003-06-10 |
Eli Lilly And Company |
Prodrugs of excitatory amino acids
|
|
JP2004035408A
(ja)
|
2002-02-15 |
2004-02-05 |
Chiron Corp |
テザシタビンを含有する安定な組成物
|
|
WO2003070754A1
(fr)
|
2002-02-20 |
2003-08-28 |
Minoru Yoshida |
Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
|
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
|
KR100974394B1
(ko)
|
2002-03-08 |
2010-08-05 |
바스프 에스이 |
프로티오코나졸을 기재로 하고 살충제를 함유하는살진균제 혼합물
|
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
|
IL149404A0
(en)
|
2002-04-29 |
2002-11-10 |
Yissum Res Dev Co |
METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
|
|
AU2003241346A1
(en)
|
2002-05-01 |
2003-11-17 |
The Cleveland Clinic Foundation |
Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
|
|
WO2003097835A2
(en)
|
2002-05-16 |
2003-11-27 |
Molecular Engines Laboratories |
Pharmaceutical compositions for the treatment of cancer
|
|
AU2003275031B2
(en)
|
2002-09-23 |
2006-08-17 |
Schering Corporation |
Novel imidazopyrazines as cyclin dependent kinase inhibitors
|
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
WO2004044218A2
(en)
|
2002-11-05 |
2004-05-27 |
The Regents Of The University Of California |
Methods and materials for examining pathways associated with glioblastoma progression
|
|
GB0226855D0
(en)
|
2002-11-18 |
2002-12-24 |
Queen Mary & Westfield College |
Histone deacetylase inhibitors
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20040197888A1
(en)
|
2002-12-31 |
2004-10-07 |
Armour Christopher D. |
Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
|
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
|
US8802116B2
(en)
|
2003-02-27 |
2014-08-12 |
Novasel Australia Pty. Ltd. |
Poloxamer emulsion preparations
|
|
CA2518407A1
(en)
|
2003-03-12 |
2004-09-23 |
Samaritan Pharmaceuticals, Inc. |
Animal model simulating neurologic disease
|
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
|
US7842835B2
(en)
|
2003-07-07 |
2010-11-30 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
|
US7514438B2
(en)
|
2003-08-13 |
2009-04-07 |
Amgen, Inc. |
Melanin concentrating hormone receptor antagonist
|
|
US20050203082A1
(en)
|
2003-08-13 |
2005-09-15 |
Hsu Chung Y. |
Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
|
|
US7378409B2
(en)
|
2003-08-21 |
2008-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
|
|
WO2005018673A1
(en)
|
2003-08-21 |
2005-03-03 |
Osaka University |
Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
|
|
US7094193B2
(en)
|
2003-08-28 |
2006-08-22 |
Philip Morris Usa Inc. |
High speed laser perforation of cigarette tipping paper
|
|
WO2005034866A2
(en)
|
2003-10-06 |
2005-04-21 |
Glaxo Group Limited |
Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
|
|
JP2007527412A
(ja)
|
2003-10-24 |
2007-09-27 |
エグゼリクシス， インコーポレイテッド |
Ｔａｏキナーゼモジュレーターおよび使用方法
|
|
JP2007511528A
(ja)
|
2003-11-13 |
2007-05-10 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
心肥大および心不全の処置としてのｔｒｐチャネル阻害方法
|
|
GB0328157D0
(en)
|
2003-12-04 |
2004-01-07 |
Imp College Innovations Ltd |
Compounds
|
|
JP2007514665A
(ja)
|
2003-12-12 |
2007-06-07 |
ミオゲン インコーポレイティッド |
エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
|
|
US8652502B2
(en)
|
2003-12-19 |
2014-02-18 |
Cordis Corporation |
Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
|
|
US20050282893A1
(en)
|
2004-01-30 |
2005-12-22 |
Au Jessie L |
Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
|
|
WO2005074941A1
(en)
|
2004-02-02 |
2005-08-18 |
Myogen, Inc. |
Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
|
|
US7253204B2
(en)
|
2004-03-26 |
2007-08-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
FR2872704B1
(fr)
|
2004-07-12 |
2007-11-02 |
Laurent Schwartz |
Pluritherapie contre le cancer
|
|
CN1586500A
(zh)
|
2004-07-19 |
2005-03-02 |
俞锋 |
治疗肿瘤的斑蝥酸钠注射剂及其制备方法
|
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
US7879569B2
(en)
|
2004-11-09 |
2011-02-01 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosis of myelodysplastic syndromes (MDS)
|
|
KR100677149B1
(ko)
|
2004-11-12 |
2007-02-02 |
삼성전자주식회사 |
잉크 조성물
|
|
EP1863804A1
(en)
|
2005-04-01 |
2007-12-12 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
CN1304396C
(zh)
|
2005-04-08 |
2007-03-14 |
中山大学 |
斑蝥素衍生物及其制备方法
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
WO2007014033A2
(en)
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
|
|
MX2008001964A
(es)
|
2005-08-10 |
2008-03-26 |
Novartis Ag |
Metodo de uso de inhibidores de desacetilasa.
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
US20070092553A1
(en)
|
2005-10-21 |
2007-04-26 |
Pfab Lp |
Compositions and methods of making rapidly dissolving lonically masked formulations
|
|
BRPI0620040A2
(pt)
|
2005-12-19 |
2011-10-25 |
Methylgene Inc |
inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos
|
|
WO2007092414A2
(en)
|
2006-02-06 |
2007-08-16 |
Lixte Biotechnology Holdings, Inc. |
Use of phosphatases to treat tumors overexpressing n-cor
|
|
ES2452820T3
(es)
|
2006-04-07 |
2014-04-02 |
Methylgene, Inc. |
Derivados de benzamida como inhibidores de histona desacetilasa
|
|
PE20080695A1
(es)
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
|
US20090018142A9
(en)
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
|
TWI449524B
(zh)
|
2006-09-07 |
2014-08-21 |
Stemline Therapeutics Inc |
以斑螫酸酐（ｃａｎｔｈａｒｉｄｉｎ）及斑螫酸酐類似物進行之癌症治療
|
|
WO2008028965A2
(en)
|
2006-09-08 |
2008-03-13 |
Institut Gustave Roussy |
Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
|
|
US20080097561A1
(en)
|
2006-10-18 |
2008-04-24 |
Medcool, Inc. |
Dual cycle thermal system and method of use
|
|
US20100137294A1
(en)
|
2006-11-15 |
2010-06-03 |
Genetic Technologies Limited |
Compounds, compositions and methods for controlling invertebrate pests
|
|
BRPI0806365B8
(pt)
|
2007-02-06 |
2021-05-25 |
Lixte Biotechnology Holdings Inc |
composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
|
|
US8413445B2
(en)
|
2007-05-11 |
2013-04-09 |
General Electric Company |
Method and system for porous flame holder for hydrogen and syngas combustion
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
WO2009020565A1
(en)
|
2007-08-03 |
2009-02-12 |
Lixte Biotechnology, Inc. |
Use of phosphates to treat neuroblastomas and medullogastomas
|
|
WO2009045440A1
(en)
|
2007-10-01 |
2009-04-09 |
Lixte Biotechnology Holdings, Inc. |
Hdac inhibitors
|
|
JP5069091B2
(ja)
|
2007-12-12 |
2012-11-07 |
三菱電機株式会社 |
監視カメラおよび監視カメラシステム
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
|
US8058268B2
(en)
|
2008-08-01 |
2011-11-15 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
|
US8227473B2
(en)
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
|
CA2730428A1
(en)
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
CN101367783A
(zh)
|
2008-10-10 |
2009-02-18 |
中国科学技术大学 |
5-羟甲基糠醛的制备方法
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
US20120135522A1
(en)
|
2009-06-18 |
2012-05-31 |
Kovach John S |
Methods of modulating cell regulation by inhibiting p53
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
WO2011094683A2
(en)
|
2010-01-29 |
2011-08-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Method of identifying myelodysplastic syndromes
|
|
EP2560634A1
(en)
|
2010-04-23 |
2013-02-27 |
Piramal Enterprises Limited |
Nitric oxide releasing prodrugs of therapeutic agents
|
|
US20140235649A1
(en)
|
2011-05-24 |
2014-08-21 |
Lixte Biotechnology, Inc. |
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
|
|
EP2755482B1
(en)
|
2011-09-15 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Combination of mk-1775 and mk-8776 for treating cancer
|
|
WO2013056211A2
(en)
|
2011-10-13 |
2013-04-18 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
|
|
BR112014029478B1
(pt)
|
2012-06-01 |
2023-01-17 |
Taisho Pharmaceutical Co., Ltd |
Compostos, fármacos de aminoácido contendo flúor e uso destes
|
|
US20150174123A1
(en)
|
2012-06-29 |
2015-06-25 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
|
|
CA2877167A1
(en)
|
2012-06-29 |
2014-01-03 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
|
|
US9738933B2
(en)
|
2012-12-05 |
2017-08-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
|
|
WO2014137741A1
(en)
|
2013-03-05 |
2014-09-12 |
Lixte Biotechnology, Inc. |
Hdac inhibitors for treating traumatic brain injury
|
|
US20160009727A1
(en)
|
2013-03-15 |
2016-01-14 |
Lixte Biotechnology, Inc. |
Sanguinarine analog pp2c inhibitors for cancer treatment
|
|
CA2909160C
(en)
|
2013-04-09 |
2021-05-25 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
EP3068398A4
(en)
|
2013-11-15 |
2017-11-15 |
Lixte Biotechnology, Inc. |
Protein phosphatase inhibitors that cross the blood brain barrier
|
|
US9051332B1
(en)
|
2013-11-20 |
2015-06-09 |
Transitions Optical, Inc. |
Photochromic indeno-fused ring pyran compounds
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
EP3137083A2
(en)
|
2014-04-28 |
2017-03-08 |
Alembic Pharmaceuticals Limited |
Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
|
|
WO2015196073A1
(en)
*
|
2014-06-20 |
2015-12-23 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
|
|
CN106572989B
(zh)
|
2014-07-24 |
2021-08-27 |
H·李·莫菲特癌症中心与研究所公司 |
用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂
|
|
CA2960989A1
(en)
|
2014-09-12 |
2016-03-17 |
Lixte Biotechnology, Inc. |
Human dosing of phosphatase inhibitor
|
|
US9994584B2
(en)
|
2014-10-15 |
2018-06-12 |
Lixte Biotechnology, Inc. |
Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
|
|
WO2016134257A1
(en)
|
2015-02-19 |
2016-08-25 |
Lixter Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
|
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
|
CN107708686B
(zh)
|
2015-05-15 |
2021-02-19 |
莱克斯特生物技术公司 |
氧杂二环庚烷前药
|
|
HK1250517A1
(zh)
|
2015-09-17 |
2018-12-21 |
Novartis Ag |
增强功效的car t细胞疗法
|
|
US20190111053A1
(en)
|
2016-01-27 |
2019-04-18 |
Lixte Biotechnology, Inc. |
Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
|
|
WO2017176289A1
(en)
|
2016-04-08 |
2017-10-12 |
Celgene Corporation |
Uses of lenalidomide and car t-cells
|
|
WO2018107004A1
(en)
|
2016-12-08 |
2018-06-14 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
US20210275521A1
(en)
|
2017-12-05 |
2021-09-09 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
|
|
WO2019241536A1
(en)
|
2018-06-14 |
2019-12-19 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for enhancing car t cell function
|
|
RU201598U1
(ru)
|
2020-05-14 |
2020-12-22 |
Андрей Владимирович Дмитриев |
Безреагентная испарительная градирня
|
|
CA3208466A1
(en)
|
2021-01-19 |
2022-07-28 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for treatment of small cell lung cancer
|
|
EP4460308A4
(en)
|
2022-01-04 |
2025-12-03 |
Lixte Biotechnology Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER OR FOR THE PREVENTION, INHIBITION OR REDUCTION OF THE RISK OF CANCER METASTASES
|